Literature DB >> 3804900

The efficacy and safety of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection.

E M Brown, R Morris, T P Stephenson.   

Abstract

The efficacy of ciprofloxacin in the treatment of chronic Pseudomonas aeruginosa urinary tract infection was assessed in 16 patients with functional or anatomical abnormalities of the urinary tract. Depending on renal function the dosage varied from 100 mg once daily to 250 mg twice daily. All patients were treated for 14 days. Bacteriological cure was documented for seven patients (44%) during the 8 week follow-up period. In a further seven patients the urine was sterile during treatment but relapse occurred within four weeks of completing the course. Persistence was noted in two cases, one of which was associated with the development of resistance. No significant adverse reactions were recorded. Chronic P. aeruginosa infection of the abnormal urinary tract can be very difficult to eradicate and ciprofloxacin may offer a valuable alternative to potentially more toxic parenteral agents.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3804900     DOI: 10.1093/jac/18.supplement_d.123

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Use of fluoroquinolone antimicrobial agents by cardiovascular and cardiopulmonary surgeons.

Authors:  H C Neu
Journal:  Tex Heart Inst J       Date:  1990

Review 2.  Treatment of genitourinary tract infections with fluoroquinolones: activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 3.  Development of resistance during antibiotic therapy.

Authors:  D Milatovic; I Braveny
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

Review 4.  Clinical experience with ciprofloxacin in the treatment of urinary tract infections: a review.

Authors:  H van Poppel; V Chyský; R Hullmann; L Baert
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 5.  Fluoroquinolone antibiotics. Microbiology, pharmacokinetics and clinical use.

Authors:  J H Paton; D S Reeves
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

6.  Ofloxacin versus trimethoprim-sulfamethoxazole for treatment of acute cystitis.

Authors:  T M Hooton; R H Latham; E S Wong; C Johnson; P L Roberts; W E Stamm
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 7.  Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.

Authors:  A Dalhoff
Journal:  Infection       Date:  1994       Impact factor: 3.553

Review 8.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 9.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.